Literature DB >> 23726928

Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.

Nazan Ozsan1, Seckin Cagirgan, Guray Saydam, Ajda Gunes, Mine Hekimgil.   

Abstract

In the 2008 WHO lymphoma classification, 'EBV-positive diffuse large B cell lymphoma (DLBCL) of the elderly is included as a new provisional entity. We aimed to evaluate the morphological, immunophenotypic, and clinical characteristics of the cases diagnosed as 'EBV-positive DLBCL of the elderly' in our center and compared them with the 'EBV-negative DLBCL' patients older than 50 years of age. EBV status was detected by Epstein-Barr early RNA (EBER) in situ hybridization analysis. By immunohistochemistry, a panel of antibodies for CD10, Bcl-2, Bcl-6, IRF4/MUM1, CD30, and Ki67 was performed. Out of 149 DLBCL patients older than 50 years, without any known history of immunodeficiency or prior lymphoma, eight patients who fulfill the criteria were re-evaluated. Five patients were male and three were female, with a median age of 67.6 years. Four patients presented with nodal involvement; others presented with bone and soft tissue, bone marrow, and spleen infiltrations. Five cases revealed predominantly monomorphic morphology, one also contained focal areas consistent with polymorphous subtype; and three patients revealed a polymorphous infiltrate. When classified according to 'Hans criteria', five were non-GCB, and three were of the GCB cell phenotype. All cases with polymorphous morphology were revealed to be of the non-GCB cell phenotype, and all expressed IRF4/MUM1. Two patients died with disease, four patients are alive and in complete remission following R-CHOP therapy, and two patients have just recently been diagnosed. When compared with the EBV-negative group, there are no reliable morphological and immunohistochemical features indicating EBV positivity. Therefore, EBER in situ hybridization analysis is necessary to identify 'EBV-positive DLBCL of the elderly'. Further studies are needed to fully understand the details of this disease, which can lead to new treatment modalities.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  EBER; EBV; Epstein-Barr virus; Epstein-Barr virus positive diffuse large B cell lymphoma of the elderly; Large B cell lymphoma; Senescence

Mesh:

Substances:

Year:  2013        PMID: 23726928     DOI: 10.1016/j.prp.2013.04.014

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.

Authors:  Ting-Xun Lu; Jin-Hua Liang; Yi Miao; Lei Fan; Li Wang; Xiao-Yan Qu; Lei Cao; Qi-Xing Gong; Zhen Wang; Zhi-Hong Zhang; Wei Xu; Jian-Yong Li
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

2.  Intraoral EBV-positive sporadic Burkitt lymphoma in an elderly patient with bilateral presentation.

Authors:  Ricardo Martínez Pedraza; Lady Paola Aristizabal Arboleda; Celeste Sánchez-Romero; Jesús Alfonso Aguirre Quiñones; Carlos de Jesús Mata Tovar; Javier Rendón Henao; Oslei Paes de Almeida
Journal:  Autops Case Rep       Date:  2019-09-18

Review 3.  Estimating the global burden of Epstein-Barr virus-related cancers.

Authors:  Yide Wong; Michael T Meehan; Scott R Burrows; Denise L Doolan; John J Miles
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-27       Impact factor: 4.553

Review 4.  How Does Epstein-Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?

Authors:  Yuxi Wen; Huan Xu; Juan Han; Runming Jin; Hongbo Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-02-23       Impact factor: 5.293

5.  Common infection-related conditions and risk of lymphoid malignancies in older individuals.

Authors:  L A Anderson; A A Atman; C M McShane; G J Titmarsh; E A Engels; J Koshiol
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.